ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Pengcheng Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9923-0241; OpenAlex author ID A5100432305. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper

Papers 2

Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in pancreatic adenocarcinoma. First author DOI 10.21037/jgo-22-333 ↗
Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.21037/apm-20-45 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Wenquan Wang · 1 shared paper, 2022 · strength 0.22
- Paper Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in panc… DOI 10.21037/jgo-22-333 ↗
Liang Liu · 1 shared paper, 2022 · strength 0.22
- Paper Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in panc… DOI 10.21037/jgo-22-333 ↗
Zijin Xu · 1 shared paper, 2022 · strength 0.22
- Paper Identification of characteristic markers correlated with Th2 cell infiltration and metabolism molecular subtype in panc… DOI 10.21037/jgo-22-333 ↗
Bo‐Ya Xiao · 1 shared paper, 2020 · strength 0.16
- Paper Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a sy… DOI 10.21037/apm-20-45 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.